Diasorin
DIA | XMIL
Overview
Corporate Details
- ISIN(s):
- IT0003492391 (+2 more)
- LEI:
- 8156002878BDF0EE4348
- Country:
- Italy
- Address:
- VIA CRESCENTINO, SNC, 13040 SALUGGIA
- Website:
- https://diasoringroup.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Diasorin is a global leader in the in vitro diagnostics (IVD) market, specializing in the development, manufacturing, and commercialization of reagent kits and automated systems. The company's core focus is on two primary segments: immunodiagnostics and molecular diagnostics. In immunodiagnostics, Diasorin provides advanced solutions, including its LIAISON® family of analyzers, which detect antibodies and antigens to aid in the diagnosis of diseases. Its molecular diagnostics division offers flexible tools that use targeted and multiplex technologies to identify pathogens in biological specimens, providing healthcare providers with critical, actionable information. The company also operates in the Licensed Technology sector, offering platforms for biomedical research, clinical diagnostics, and drug discovery to help scientists find rapid and reliable answers to complex biological questions.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Diasorin.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-07 11:29 |
Interim Report
Interim Financial Report as at June 30, 2025
|
English | 3.0 MB | |
| 2025-08-04 16:51 |
Report Publication Announcement
Pubblicazione della Relazione finanziaria semestrale al 30 giugno 2025
|
Italian | 184.4 KB | |
| 2025-08-04 15:32 |
Interim Report
Relazione Finanziaria Semestrale del Gruppo Diasorin al 30 giugno 2025
|
Italian | 3.4 MB | |
| 2025-07-31 16:24 |
Investor Presentation
Diasorin H1 2025 Results Presentation
|
English | 1.4 MB | |
| 2025-07-31 16:22 |
Earnings Release
Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed
|
English | 342.3 KB | |
| 2025-07-31 16:21 |
Earnings Release
Ricavi in crescita ed incremento della marginalità nel 1° semestre 2025. Confer…
|
Italian | 470.4 KB | |
| 2025-07-07 09:34 |
Regulatory News Service
Communication on total amount of voting rights
|
Italian | 210.5 KB | |
| 2025-07-07 09:32 |
Regulatory News Service
Comunicazione dell'ammontare complessivo dei diritti di voto
|
Italian | 232.4 KB | |
| 2025-07-01 08:57 |
Transaction in Own Shares
Diasorin S.p.A. - Allegato 3F
|
Italian | 91.4 KB | |
| 2025-05-12 15:37 |
Post-Annual General Meeting Information
Pubbicazione del verbale dell'Assemblea degli Azionisti del 28 aprile 2025
|
Italian | 184.1 KB | |
| 2025-05-12 15:26 |
Post-Annual General Meeting Information
Verbale Assemblea Ordinaria degli Azionisti 28 aprile 2025
|
English | 21.1 MB | |
| 2025-05-06 17:43 |
Investor Presentation
Diasorin Q1 2025 Results Presentation
|
English | 1.4 MB | |
| 2025-05-06 17:39 |
Earnings Release
Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidan…
|
English | 369.9 KB | |
| 2025-05-06 17:38 |
Earnings Release
Ricavi in crescita dell’8% ed EBITDA Margin al 34%: i risultati del 1° trimestr…
|
Italian | 417.5 KB | |
| 2025-04-29 12:52 |
Post-Annual General Meeting Information
Shareholders' Meeting April 29, 2025 - Summary report on votes
|
English | 224.5 KB |
Automate Your Workflow. Get a real-time feed of all Diasorin filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Diasorin via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
